Sponsor Check › Person
Related person on Form D filings · address states as listed: CT, NH, NY, MA, PA, NJ · listed Oct 23, 2015 → Sep 29, 2026
Data last updated: Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: not yet · SEC enforcement last checked: not yet
Privacy: business-related public information only. Residential addresses are never shown; only the state from the filing.
The five facts investors ask about first. Each section states what was searched and when. Items still in human review are not shown.
Not yet searched.
Sources to be searched: CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Search queued. Results are added automatically; check back later or follow this page to be notified.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — not yet searched; State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states: not yet searched.
Not yet searched.
Search queued. Results are added automatically; check back later or follow this page to be notified.
Not yet searched.
Sources to be searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Search queued. Results are added automatically; check back later or follow this page to be notified.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
Comparisons are made for sponsors and sponsor groups, not individual people.
1 of 21 offerings reports sales commissions totalling $4,700,000; 0 report finder's fees; 1 reports proceeds to related persons totalling $1,710,000. (includes amounts the issuer reported as estimates)
| Source | Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it |
|---|---|---|---|---|---|
| EDGAR ↗ | Sep 29, 2026 D/A File 021-559127 | $0 (est.) | $0 (est.) | $0 (est.) The special limited partner is entitled to carried interest. The investment manager is entitled to a management fee. The carried interest and management fee are fully discussed in the Issuer's confidential offering materials. | J.P. Morgan Institutional Investments Inc. BrokerCheck CRD 102920 ↗ J.P. Morgan Securities LLC BrokerCheck CRD 79 ↗ |
| EDGAR ↗ | Sep 29, 2026 D/A File 021-559129 | $0 (est.) | $0 (est.) | $0 (est.) The special shareholder is entitled to carried interest. The investment manager is entitled to a management fee. The carried interest and management fee are fully discussed in the Issuer's confidential offering materials. | J.P. Morgan Institutional Investments Inc. BrokerCheck CRD 102920 ↗ J.P. Morgan Securities LLC BrokerCheck CRD 79 ↗ |
| EDGAR ↗ | Sep 16, 2026 D File 021-597633 | $0 (est.) | $0 (est.) | $0 (est.) The special limited partner is entitled to carried interest. The investment manager is entitled to a management fee. The carried interest and management fee are fully discussed in the Issuer's confidential offering materials. | J.P. Morgan Securities LLC BrokerCheck CRD 79 ↗ J.P. Morgan Institutional Investments Inc. BrokerCheck CRD 102920 ↗ |
| EDGAR ↗ | Sep 16, 2026 D File 021-597634 | $0 (est.) | $0 (est.) | $0 (est.) The special limited partner is entitled to carried interest. The investment manager is entitled to a management fee. The carried interest and management fee are fully discussed in the Issuer's confidential offering materials. | J.P. Morgan Securities LLC BrokerCheck CRD 79 ↗ J.P. Morgan Institutional Investments Inc. BrokerCheck CRD 102920 ↗ |
| EDGAR ↗ | Mar 20, 2026 D/A File 021-510828 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 13, 2023 D File 021-496947 | $0 (est.) | $0 (est.) | $0 (est.) The special limited partner is entitled to carried interest. The investment manager is entitled to a management fee. The carried interest and management fee are fully discussed in the Issuer's confidential offering materials. | J.P. MORGAN INSTITUTIONAL INVESTMENTS INC. BrokerCheck CRD 102920 ↗ JPMORGAN ASSET MANAGEMENT (JAPAN) LIMITED no CRD number reported JPMORGAN ASSET MANAGEMENT (EUROPE) S.A.R.L. BrokerCheck CRD 304190 ↗ JPMORGAN ASSET MANAGEMENT (UK) LIMITED no CRD number reported |
| EDGAR ↗ | Sep 5, 2023 D File 021-491365 | $0 (est.) | $0 (est.) | $0 (est.) The special limited partner is entitled to carried interest. The investment manager is entitled to a management fee. The carried interest and management fee are fully discussed in the Issuer's confidential offering materials. | J.P. Morgan Institutional Investments Inc. BrokerCheck CRD 102920 ↗ JPMorgan Asset Management (UK) Limited BrokerCheck CRD 135960 ↗ JPMorgan Asset Management (Japan) Limited no CRD number reported JPMorgan Asset Management (Europe) S.a r.l. BrokerCheck CRD 304190 ↗ |
| EDGAR ↗ | Sep 5, 2023 D File 021-491366 | $0 (est.) | $0 (est.) | $0 (est.) The special shareholder is entitled to carried interest. The investment manager is entitled to a management fee. The carried interest and management fee are fully discussed in the Issuer's confidential offering materials. | J.P. Morgan Institutional Investments Inc. BrokerCheck CRD 102920 ↗ JPMorgan Asset Management (UK) Limited BrokerCheck CRD 135960 ↗ JPMorgan Asset Management (Japan) Limited no CRD number reported JPMorgan Asset Management (Europe) S.a r.l. BrokerCheck CRD 304190 ↗ |
| EDGAR ↗ | Dec 8, 2022 D File 021-466966 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 28, 2021 D/A File 021-400266 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 1, 2020 D File 021-370112 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 1, 2020 D File 021-370115 | $4,700,000 | $0 | $0 | Raymond James & Associates, Inc. BrokerCheck CRD 705 ↗ B. Riley FBR, Inc. BrokerCheck CRD 25027 ↗ Katalyst Securities LLC BrokerCheck CRD 112494 ↗ |
| EDGAR ↗ | Sep 6, 2019 D File 021-348117 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 12, 2019 D File 021-337163 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 10, 2018 D File 021-312119 | $0 | $0 | $0 (est.) | None listed on this filing |
| EDGAR ↗ | Apr 5, 2018 D File 021-309449 | $0 | $0 | $0 No payments other than ordinary course employment compensation is being paid to officers or managers. | None listed on this filing |
| EDGAR ↗ | Mar 9, 2018 D/A File 021-114791 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 9, 2018 D/A File 021-176983 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 1, 2017 D File 021-293982 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 21, 2016 D/A File 021-242888 | $0 | $0 | $1,710,000 (est.) | None listed on this filing |
| EDGAR ↗ | Oct 23, 2015 D File 021-249974 | $0 | $0 | $0 No payments other than ordinary course employment compensation is being paid to officers or directors. | None listed on this filing |
As reported by the issuer on Form D (Items 12–15), latest filing per offering (one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.
Counted across every filing this person is listed on (latest filing per offering, per issuer).
| Source | Issuer | Role | Filed | Form | Offering | Sold | Investors | Min. investment |
|---|---|---|---|---|---|---|---|---|
| EDGAR ↗ | 270 Healthcare Growth Fund I LP group: Comvest | Executive Officer | Sep 29, 2026 | D/A | Indefinite similar: $155,000–$5,250,000 | $113,926,000 | 27 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | 270 Healthcare Growth Fund I (LUX) SCSp-RAIF group: Comvest | Executive Officer | Sep 29, 2026 | D/A | Indefinite similar: $155,000–$5,250,000 | $113,926,000 | 18 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | 270 Life Sciences Private Capital Fund II (Cayman) LP group: Comvest | Executive Officer | Sep 16, 2026 | D | Indefinite similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | 270 Life Sciences Private Capital Fund II (US) LP group: Comvest | Executive Officer | Sep 16, 2026 | D | Indefinite similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Averna Therapeutics Inc. | Director | Mar 20, 2026 | D/A | $85,000,000 similar: $829,831–$9,999,998 | $84,999,995 | 13 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | 270 Healthcare Growth Fund I (LUX) SCSp-RAIF group: Comvest | Executive Officer | Sep 29, 2025 | D | Indefinite similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | 270 Healthcare Growth Fund I LP group: Comvest | Executive Officer | Sep 29, 2025 | D | Indefinite similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Averna Therapeutics Inc. | Director | Apr 21, 2025 | D/A | $85,000,000 similar: $829,831–$9,999,998 | $43,769,227 | 13 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Averna Therapeutics Inc. | Director | Apr 17, 2024 | D | $85,000,000 similar: $829,831–$9,999,998 | $38,769,227 | 13 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | 270 Life Sciences Private Capital Employee Fund I LP group: Comvest | Executive Officer | Nov 13, 2023 | D | Indefinite similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | 270 Life Sciences Private Capital Fund I (Lux) SCSp-RAIF group: Comvest | Executive Officer | Sep 5, 2023 | D | Indefinite similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | 270 Life Sciences Private Capital Fund I LP group: Comvest | Executive Officer | Sep 5, 2023 | D | Indefinite similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Gennao Bio, Inc. group: Comvest | Executive Officer, Director, Promoter Dr. Squinto is the Executive Chairman of the Issuer. | Dec 8, 2022 | D | $40,000,000 similar: $2,000,000–$19,999,994 | $14,999,997 | 3 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Gennao Bio, Inc. group: Comvest | Executive Officer, Director, Promoter Dr. Squinto is the Chief Executive Officer, Executive Chairman, President and Treasurer. | Dec 28, 2021 | D/A | $55,000,012 similar: $2,000,000–$19,999,994 | $32,500,008 | 7 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Gennao Bio, Inc. group: Comvest | Executive Officer, Director, Promoter Dr. Squinto is the Executive Executive Officer, Chairman, President, Treasurer and Secretary of the Issuer. | May 21, 2021 | D | $40,000,019 similar: $2,000,000–$19,999,994 | $10,000,005 | 3 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Compass Therapeutics, Inc. group: Compass Therapeutics | Director | Jul 1, 2020 | D | $70,000,000 similar: $500,000–$7,000,000 | $60,482,210 | 110 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Compass Therapeutics, Inc. group: Compass Therapeutics | Director | Jul 1, 2020 | D | $195,276,780 similar: $500,000–$7,000,000 | $195,276,780 | 114 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Passage BIO, Inc. group: Comvest | Executive Officer, Director | Sep 6, 2019 | D | $110,000,000 similar: $829,831–$9,999,998 | $109,999,974 | 15 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | SpringWorks Therapeutics, Inc. group: Springworks Therapeutics | Director | Apr 12, 2019 | D | $125,003,152 similar: $829,831–$9,999,998 | $125,003,152 | 26 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | UCAN Co | Director | May 10, 2018 | D | $5,749,976 similar: $2,000,000–$19,999,994 | $5,749,976 | 9 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | ARVINAS, INC. group: Arvinas | Director Manager | Apr 5, 2018 | D | $55,000,000 similar: $2,000,000–$19,999,994 | $55,000,000 | 22 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | UCAN Co | Director | Mar 9, 2018 | D/A | $2,515,103 similar: $2,000,000–$19,999,994 | $2,515,103 | 14 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | UCAN Co | Director | Mar 9, 2018 | D/A | $2,519,976 similar: $2,000,000–$19,999,994 | $2,519,976 | 46 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | SpringWorks Therapeutics, LLC group: Springworks Therapeutics | Director | Sep 1, 2017 | D | $103,000,000 similar: $829,831–$9,999,998 | $12,815,535 | 4 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Compass Therapeutics LLC group: Compass Therapeutics | Director | Sep 21, 2016 | D/A | $170,205,999 similar: $2,000,000–$19,999,994 | $45,977,738 | 17 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | ARVINAS, INC. group: Arvinas | Director | Oct 23, 2015 | D | $41,609,999 similar: $2,000,000–$19,999,994 | $41,609,999 | 16 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Compass Therapeutics LLC group: Compass Therapeutics | Director | Jul 1, 2015 | D | $120,977,535 similar: $2,000,000–$19,999,994 | $15,977,535 | 11 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | UCAN Co | Director | Apr 19, 2012 | D | $2,500,000 similar: $2,000,000–$19,999,994 | $620,628 | 14 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | UCAN Co | Director | Dec 9, 2010 | D/A | $2,499,999 similar: $2,000,000–$19,999,994 | $1,859,316 | 46 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | UCAN Co | Director | Dec 24, 2009 | D | $2,499,999 similar: $2,000,000–$19,999,994 | $624,446 | 22 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
Every row is a Form D or D/A on which the issuer listed this name as a related person. Related-person names are matched on first + last name and the address state on the filing; records that share a name but could not be tied together by a second identifier are listed separately below.
"Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); Other Health Care / 506(b) (4,189 filings); Biotechnology / 506(b) (3,253 filings); Other / 506(b) (18,678 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Not linked to this profile — a second identifier (same issuer, same sponsor group) was not found. Could be the same person or a different one.
People and management entities the issuers listed as related persons on the same Form D filings as Stephen Squinto. Source: the EDGAR rows in the table above. Showing the 40 with the most shared filings.
None found in sources searched.
Sources searched: SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 · Last checked Oct 23, 2026, 8:41 PM ET.
Export this report as PDF (members · included free during the launch period)
No corrections have been requested for this page.
Free. Logged with status: received → under review → fixed / confirmed with source.
If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.
Members get an email when Stephen Squinto appears on a new Form D, or when a court case or SEC action is matched to them. See plans →